Genes from algae helped a blind man recover some of his vision – Livescience.com

A blind man who could only perceive the faintest bit of light can now perceive fuzzy shapes, thanks to gene therapy and a pair of specially engineered goggles.

The man was diagnosed with a condition called retinitis pigmentosa 40 years ago, at the age of 18, according to a new report, published Monday (May 24) in the journal Nature Medicine. People with retinitis pigmentosa carry faulty genes that, due to many mutations, cause the light-sensitive cells in the retina at the back of the eye to break down, according to the National Eye Institute (NEI).

These genes would usually code for functional proteins in the retina, but instead fail to build those proteins, or make abnormal proteins that malfunction or produce substances that directly damage the retinal tissue. The condition affects roughly 1 in 4,000 people worldwide, according to the NEI, and can sometimes lead to complete blindness, as occurred in the 58-year-old patient in the new study, BBC News reported.

Related: 12 amazing images in medicine

In an attempt to treat the man's vision loss, scientists inserted genes that code for a light-sensing protein into a modified virus, then injected those genetically tweaked viral vectors into one of his eyes, the researchers reported. The protein, called ChrimsonR, is a engineered version of a light-sensitive protein found in unicellular algae, which allows the single-celled organism to detect and move toward sunlight, MIT Technology Review reported.

ChrimsonR belongs to a family of light-sensitive proteins called channelrhodopsins, hence the added "H" in crimson, and has been modified to react to colors within the reddish end of the color spectrum, namely amber light. By injecting genes for ChrimsonR into the retina specifically into retinal ganglion cells, a kind of nerve cell that sends visual signals to the brain the team hoped to make these cells sensitive to yellow-orange light, MIT Technology Review reported.

Here's where the special goggles came in. The goggles pick up changes in light intensity from the environment and then translate that signal into an intense, amber image that gets projected straight onto the patient's retina, with the aim of activating ChrimsonR. Months passed before a significant quantity of ChrimsonR accumulated in the man's eye and began to alter his vision, but eventually, he began to perceive patterns of light with help from the goggles, BBC News reported.

"The patient perceived, located, counted and touched" different objects using his treated eye, alone, and while wearing the goggles, the researchers wrote in the study. For instance, the patient could perceive a notebook and cups placed on a table in front of him, although when asked to count the cups he did not always give the correct number, according to MIT Technology Review.

Prior to receiving the therapy, the man could not detect any objects, with or without the goggles on, and following the injection, he could only see while wearing the goggles, since they convert all light into an amber hue, the researchers reported.

In addition to the notebook and cups, the patient reported being able to see the painted white lines at a pedestrian crossing, the BBC reported. "This patient initially was a bit frustrated because it took a long time between the injection and the time he started to see something," first author Dr. Jos-Alain Sahel, an ophthalmologist and scientist at the University of Pittsburgh and Institute of Vision in Paris, told the BBC. The patient began training with the goggles about 4.5 months after his injection and only started reporting improvements in his vision about 7 months after that, the team reported.

"But when he started to report spontaneously he was able to see the white stripes to come across the street you can imagine he was very excited. We were all excited," Sahel told the BBC.

Even now, the man's vision still remains fairly limited, in that he can only see monochromatic images and at a fairly low resolution. But "the findings provide proof-of-concept that using optogenetic therapy to partially restore vision is possible," senior author Dr. Botond Roska, founding director of the Institute of Molecular and Clinical Ophthalmology Basel at the University of Basel, told BBC News. ("Optogenetics" broadly describes the technique of using light and genetic modification to control the activity of neurons.)

Of course, although these initial results are exciting, the study is limited in that only one patient has received the treatment so far, James Bainbridge, a professor of retinal studies at the University College London who was not involved in the study, told the BBC.

Read more about the research in BBC News and MIT Technology Review.

Originally published on Live Science.

See the rest here:
Genes from algae helped a blind man recover some of his vision - Livescience.com

Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline – Business Wire

CAMBRIDGE, Mass. & FARGO, N.D.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing and diagnostic applications, have announced their expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in Modernas clinical development pipeline.

Specifically, Aldevron will supply plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Modernas pipeline.

Aldevron has been a long-standing partner of Moderna. We appreciate their collaboration and their expertise in the biologics space, said Juan Andres, Chief Technical Operations and Quality Officer of Moderna. We look forward to our ongoing work with this expanded partnership.

Aldevrons support of the Moderna pipeline spans nearly a decade, and were incredibly proud of the trust theyve placed in us commented Kevin Ballinger, Chief Executive Officer of Aldevron. Our deep experience, coupled with enhanced operational efficiencies and recent capacity expansion place us in an excellent position to support Modernas efforts especially during this critical time. We look forward to expanding our strategic partnership to serve a pipeline of important new programs in the future.

Aldevrons production of DNA continues to take place in its 70,000 sq ft GMP facility located in Fargo, North Dakota. Buildout and validation of an additional 189,000 sq ft expansion to the GMP facility on Aldevrons 14-acre Breakthrough Campus has been completed, enabling additional manufacturing capacity.

About Aldevron

Aldevron is a premier manufacturing partner in the global genetic medicine field. Founded in 1998 by Michael Chambers and John Ballantyne, the company provides critical nucleic acids and proteins used to make gene and cell therapies, DNA and RNA vaccines, and gene editing technologies. Aldevrons 600 employees support thousands of scientists who are developing revolutionary treatments for millions of people.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Modernas capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Modernas mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 14 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit http://www.modernatx.com.

Modernas Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the supply by Aldevron of plasmid DNA for Moderna products, including the Companys COVID-19 vaccine. In some cases, forward-looking statements can be identified by terminology such as will, may, should, could, expects, intends, plans, aims, anticipates, believes, estimates, predicts, potential, continue, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Modernas control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of the Moderna COVID-19 Vaccine observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with Modernas regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for the Moderna COVID-19 Vaccine; whether and when any biologics license applications and/or emergency use authorization applications may be filed and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading Risk Factors in Modernas most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SECs website at http://www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Modernas current expectations and speak only as of the date hereof.

Originally posted here:
Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline - Business Wire

CRISPR Therapeutics to Participate in Upcoming Investor – GlobeNewswire

ZUG, Switzerland and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in June:

Jefferies Virtual Healthcare ConferenceDate: Tuesday, June 1, 2021Time: 1:00 p.m. ET

William Blair 41st Annual Growth Stock ConferenceDate: Thursday, June 3, 2021Time: 12:20 p.m. ET

Goldman Sachs 42nd Annual Global Healthcare ConferenceDate: Tuesday, June 8, 2021Time: 3:00 p.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR THERAPEUTICS word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investors:Susan Kim, +1 617-307-7503susan.kim@crisprtx.com

Media:Rachel Eides, +1-617-315-4493Rachel.Eides@crisprtx.com

Visit link:
CRISPR Therapeutics to Participate in Upcoming Investor - GlobeNewswire

ARM, EFPIA and EuropaBio Call for Advanced Therapies to be – GlobeNewswire

Alliance for Regenerative Medicine, European Federation of Pharmaceutical Industries and Associations, and European Association for Bioindustries Call for Advanced Therapies to be Exempt from EU GMO Legislation

COVID-19 highlights how the EU can adapt legislation to meet urgent health needs

A permanent exemption would help to accelerate access to life-changing medicines for European patients

BRUSSELS, BELGIUM May 25, 2021

The European Commission should exempt advanced therapies from Genetically Modified Organism (GMO) legislation, which hurts Europes ability to attract clinical trials and delays patient access to transformative medicines, said the Alliance for Regenerative Medicine (ARM), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the European Association of Bioindustries (EuropaBio) in a paper published online yesterday in the journal Human Gene Therapy.

The European Commission recognized that GMO requirements hinder the conduct of clinical trials in its April 29 study on new genomic techniques and in the 2020 Pharmaceutical Strategy for Europe, when it called for GMO legislation to be fit for purpose for addressing medicines. The original GMO legislation was primarily enacted to protect food consumers and the environment, but Advanced Therapy Medicinal Products (ATMPs) such as gene therapies are affected as an unintended consequence. The uneven application of GMO requirements across EU Member States causes significant clinical trial delays despite findings that gene therapies pose a negligible risk to the environment.

Galvanized by the pandemic, the European Commission granted a temporary derogation from GMO requirements to investigational COVID-19 medicinal products to accelerate the development of vaccines and treatments. An industry survey suggested that the temporary derogation decreased the amount of time required to complete clinical trials in Europe. A similar, but permanent, exemption is justified for gene therapies -- which often treat life-threatening diseases that have few, or no, treatment options while still preserving high quality and safety standards.

The European Commission recognised that time was of the essence when lifting GMO requirements for COVID-19 vaccines and treatments, said Paige Bischoff, ARMs Senior Vice President of Global Public Affairs. Time is also very much of the essence for people with cancer, inherited disorders and other life-threatening conditions. We call on the European Commission to take the same measures for advanced therapies and remove the unnecessary and unintended burden of GMO legislation so patients have timely access to transformative, potentially curative medicines.

The organisations call on the European Commission to put forward a proposal by 2022, the timeframe proposed by the Pharmaceutical Strategy for Europe. Without an exemption for gene therapies, the GMO requirements threaten the regions competitiveness with other parts of the world where GMO legislation is less complex and cumbersome. A 2019 ARM report, for example, found that the number of ATMP clinical trials in Europe stayed roughly flat over a four-year period (2014-2018) while increasing substantially in North America (+36%) and in Asia (+28%). Europe is at risk of falling further behind: At the end of 2020 the ATMP sector was conducting 1,220 clinical trials worldwide, up from 1,066 in 2019.

"In 2020, we welcomed the derogation from GMO legislation for COVID-19 treatments or vaccines in clinical trials, said Pr Tellner,Director of Regulatory Affairs at EFPIA. Member companies are increasingly reporting how the derogation has removed the significant and time-consuming hurdles associated with GMO submissions, in addition to the clinical trial application. Swift action to a permanent exemption from GMO legislation allows the EU to prosper and most importantly for patients to continue to receive transformative, potentially life-saving therapies."

Freeing the conduct of clinical trials with investigational gene therapies from the heavy EU GMO administrative burden is critical for cutting-edge biotechnology companies, added Violeta Georgieva, EuropaBios Legal Affairs Manager. The use of CRISPR/Cas9, the latest promising tool in genome editing, can be overshadowed in the EU if developers and regulators are to follow the 2018 ruling of the EU Court of Justice, which puts the controversial GMO label on the Nobel Prize-winning CRISPR technology. Our hopes are set on the European Commission to improve patient access to revolutionary treatments by exempting them from the disproportionate and outdated GMO framework.

ARM, EFPIA, and EuropaBio look forward to engaging with the European Commission and other stakeholders to find the best possible solutions to ensure that Europe is a competitive destination for the development of advanced therapies and that European patients have access to the most innovative, life-changing treatments.

Press enquiries

For more information or for media requests, please contact Stephen Majors from the Alliance for Regenerative Medicine at smajors@alliancerm.org, Andy Powrie-Smith from EFPIA at communications@efpia.eu, or Dovile Sandaraite from EuropaBio at d.sandaraite@europabio.org.

About the Alliance for Regenerative Medicine (ARM)

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organisation dedicated to realizing the promise of advanced therapy medicinal products (ATMPs).ARMpromotes legislative, regulatory, reimbursement and manufacturing initiativesin Europe and internationally to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies.Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing ATMPs.In its 11-year history,ARMhas become the global voice of the sector, representing the interests of 380+ members worldwide and 85+ members across 15 Europeancountries, including small and large companies, academic research institutions, major medical centres and patient groups.To learn more aboutARMor to become a member, visithttp://www.alliancerm.org.

About the European Federation of Pharmaceutical Industries and Associations (EFPIA)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 36 national associations, 39 leading pharmaceutical companies and a growing number of small and medium- sized enterprises (SMEs), EFPIAs mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy

About the European Association for Bioindustries (EuropaBio)

The European Association for Bioindustries (EuropaBio) promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 1800 biotech SMEs. Read more about our work at http://www.europabio.org.

See the article here:
ARM, EFPIA and EuropaBio Call for Advanced Therapies to be - GlobeNewswire

What We’re Reading: Restoring Eyesight; New Moderna Vaccine Indication Possible; COVID-19 Origin Investigation – AJMC.com Managed Markets Network

Optogenics was used to partially restore a blind mans eyesight; the FDA could soon approve Modernas COVID-19 vaccine for use among adolescents; HHS calls for a new investigation into COVID-19s origins.

Light-catching proteins were grown in the eye of a blind man in France who, with the help of special goggles, can now see blurred outlines of objects, reports an article in Nature Medicine. This novel form of gene therapy is optogenics, and these results mark its first successful use against a neurodegenerative eye disease, which rob[s] the eyes of essential proteins required for vision. The treatment transforms ganglion cells into new photoreceptor cells, with the scientists also utilizing algae-derived proteins to sensitize nerve cells to light.

Hoping to gain approval for its COVID-19 vaccine among adolescents aged 12 to 17 years, Moderna will submit effectiveness data to the FDA in June, reports The New York Times. Currently only available for persons 18 years and older, the new vaccine data comprise results from 3732 participants. Most notably, efficacy was shown to be 100%, following no reports of symptomatic COVID-19 in the two-thirds who received both doses. Pfizers vaccine was similarly approved for use among adolescents aged 12 to 15 years on May 10.

Following US intelligence reports that Chinese virology experts were seriously ill before cases of COVID-19 were ever reported in December 2019, HHS Secretary Xavier Becerra is seeking a more transparent phase 2 investigation into the beginnings of the COVID-19 pandemic, according to Reuters. This new effort should again be headed by an international team, he added. Speaking for the World Health Organization (WHO), whose previous report on the pandemics origins was met with much criticism, spokesperson Tarik Jasarevic noted that the next step will be to present a proposal to WHO Director-General Tedros Adhanom Ghebreyesus on studies that cover early detection of cases and clusters and food chain transmission, among others.

Read the original here:
What We're Reading: Restoring Eyesight; New Moderna Vaccine Indication Possible; COVID-19 Origin Investigation - AJMC.com Managed Markets Network

Kathleen Loonie ’21: Rising Researcher – UMass News and Media Relations

UMass Amherst pre-veterinary sciences major uses gene sequencing to advance immunology research

As a young girl dreaming of becoming a veterinarian, Kate Loonie may have expected some of the hands-on experiences she had at UMass Amherst. She vaccinated and ear-tagged Belted Galloway cattle, medicated injured horses, helped deliver lambs, and even cared for turtles as a summer intern at the New England Aquarium. But she didnt expect that some of her most fulfilling work would be performing gene sequencing on a computer.

I never saw myself doing research, especially in my undergraduate years, Kate says. I didnt think I would enjoy lab work. But it pushed me to places I didnt think Id be able to go.

Working in the lab of Professor of Veterinary and Animal Sciences Cynthia Baldwin beginning in her freshman year, Kate has been involved in three cellular immunology research projects related to tracking down a gene family, known as WC1, in sheep, cattle, and goats. She graduated from UMass with her name on three published research papers.

Although genetic sequences at first looked like alphabet soup to her, Kate learned the Baldwin labs bioinformatics technology quickly. I practiced and practiced that tedious software every moment I could, she recalls. Baldwin noted that Kate is a good collaborator who is proactive in the lab. She is really passionate about learning new techniques and is a very mature, independent, and responsible individual, she said.

Having learned the software, Kate was given an independent projectlooking at the gene sequences of the auroch, the ancient ancestors of our modern-day cattle. The auroch, immortalized in cave paintings, were massive super cattle that lived in Asia, Europe, and North Africa before their extinction in 1627. Kate sequenced the DNA from a 6,000 year-old auroch humerus bone and gathered evidence of the presence of WC1. I concluded that some bovine WC1 molecules were preserved from the ancient auroch, while some molecules seem to have been lost or created from evolution. This shows its possible the aurochs were seeing the same pathogens as were seeing today, she says. This research has important implications for improving the health of ruminants.

For her second published project, Kate amalgamated data from numerous years of study and used gene sequencing technology to investigate WC1 in sheep. Her third published paper is titled, Special features of T cells in ruminants. Kates thesis, Investigating gene expression in T cells, contributes toward understanding cells that could point the way toward more effective vaccines.

For Kate, lab work revealed the true potential of the impact a veterinarian can have in research. Research made me stop and think, she says. I started to think about situations differently and more analytically both in the lab and out of the lab, in classes, at the cattle barn, and everywhere else. I caught a glimpse of the potential I will have with more education, and how much I can contribute to developing science and knowledge in my future. With that, I relit my passion for veterinary science.

Kate will begin studying for her doctor in veterinary medicine degree at Cornell University this summer. After I have established my veterinary career, she says, I can see myself pursuing a masters or PhD in the research realm. I hope to teach the young undergraduate generation of pre-veterinary students.

Link:
Kathleen Loonie '21: Rising Researcher - UMass News and Media Relations

NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer – GlobeNewswire

PITTSBURGH, May 25, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appointment of Kia Motesharei, Ph.D., as Chief Business and Strategy Officer, effective May 24, 2021. Dr. Motesharei has more than 20 years of experience in business development, licensing and transactions, alliance management and strategy in the biotechnology and pharmaceutical industry.

Kia has successfully completed more than 100 deals, with particular expertise in scaling the output of platform biotechnology companies through partnerships to maximize shareholder value, with several drugs on market now as a direct result of his activities. Kia also has expertise in our programmatic areas including in neurology, oncology and rare diseases, said Dietrich A. Stephan, Ph.D., Founder, CEO and Chairman of NeuBase. We are excited to welcome Kia to the NeuBase team, as we evaluate potential partnership opportunities and expand our therapeutic pipeline, leveraging the broad capabilities of our PATrOLTM platform for precision genetic medicines.

Genetic mutations are the fundamental drivers of all diseases, rare and common, so NeuBases ability to specifically modulate mutated DNA and RNA can unlock a whole new class of medicines for diseases that currently have few treatment options, said Dr. Motesharei. I look forward to utilizing partnership strategies to expand the breadth of what we have the potential to accomplish with this technology to benefit patients around the world.

Most recently, Dr. Motesharei was Senior Vice President, Business Development & Corporate Strategy at Akcea Therapeutics, a late-stage development and commercial biopharmaceutical company focused on rare diseases, where he led and executed the regional partnership of Akceas marketed products Tegsedi and Waylivra with Sobi in Europe and the Middle East. Prior to Akcea, Dr. Motesharei headed Global Licensing & Business Development, Neurology & Immunology (N&I) at EMD Serono, the biopharmaceutical business of Merck KGaA. He was a core member of the N&I Franchise Leadership Team that executed the overall strategy of the $1.8 billion franchise, including product and pipeline development, partnering, regulatory and commercial and marketing decisions. He managed the global licensing team responsible for search and evaluation and transactions across the entire R&D spectrum for the immunology, neurology, allergy, fertility, medical device and global health franchises. Previously, Dr. Motesharei was a member of the management team and investor relations team at Dyax Corporation, a pharmaceutical company focused on development and commercialization of novel biotherapeutics for prevention of hereditary angioedema. He led the business development, alliance management and competitive intelligence functions covering Dyaxs phage display platform as well as pipeline products including Kalbitor and DX-2930 (now approved as Takhzyro) that contributed to its approximately $6.5 billion acquisition by Shire. Earlier in his career, he held a series of leadership positions at Genfit Corporation, ActivX Biosciences and Lion Bioscience. He currently serves on the board of Ariana Pharma. Dr. Motesharei received a Ph.D. in organic chemistry from the UCLA and a B.A. in chemistry from Colorado College. He completed his postdoctoral training as an NIH fellow at The Scripps Research Institute.

About NeuBase TherapeuticsNeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBases targeted PATrOL therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit http://www.neubasetherapeutics.com.

Use of Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These forward-looking statements include, among others, those related to Dr. Moteshareis leadership and development experience guiding the Company as it advances its preclinical portfolio and discovery and drug development platform and towards clinical trials and beliefs that Dr. Moteshareis ability will help the growth of the Company. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission (the SEC), may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company's plans to develop and commercialize its product candidates; the timing of initiation of the Company's planned clinical trials; the risks that prior data will not be replicated in future studies; the timing of any planned investigational new drug application or new drug application; the Company's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company's product candidates; the Company's commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the SEC. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

NeuBase Investor Contact:Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com OP: (617) 430-7576

NeuBase Media Contact:Jessica Yingling, Ph.D.Little Dog Communications Inc.(858) 344-8091jessica@litldog.com

See the article here:
NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer - GlobeNewswire

Companies Unlocking a New Class of Cancer Therapies with Sensitive METTL3 Tuning – BioSpace

University of Cambridge researchers published the first preclinical validation for a novel therapeutic strategy targeting epitranscriptomic modifiers of RNA, opening the door for spinout STORM Therapeutics acute myeloid leukemia therapy (AML)and potentially much more.

Tony Kouzarides, cofounder and director of Milner Therapeutics Institute at Cambridge and a Storm co-founder, led the team that published the paper in Nature in April, which was the first published data showing the efficacy of a catalytic METTL3 inhibitor in mouse models of AML.

Consistent with earlier findings on METTL3s role in regulating disease, Storms STM2457 decreased AML engraftment and increased survival. Last year the company nominated a related compound as its lead clinical candidate, and Kouzarides said Storm expects it will reach clinical testing early next year.

This is the first published in vivo data for a small molecule inhibiting an epitranscriptomic disease target, but the approach has been brewing for years. Just as epigenetic modifications to DNA can directly control gene expression, epitranscriptomic modifications control RNA gene expression indirectly via RNA translation, making them potential therapeutic targets. While the first epigenetic therapy was approved in 2004, the connection between epitranscriptomic modifiers and disease pathways have only begun to be characterized.

METTL3 is an epigenetic writer of N6-methyladenosine (m6A) modifications, the most prevalent reversable epitranscriptomic modification in human cells. METTL3 and other writers form m6A modifications via methylation of certain RNA sequences, which is key for numerous processes in normal cells. This would seem to make it an unlikely therapeutic target.

But in 2017, two key publications began to elucidate the role of m6A in AML and demonstrate the possibility of targeting the pathway without toxicity in healthy cells. Kouzarides and colleagues published findings showing the role of METTL3 in both establishing disease and in leukemia cell differentiation.

Separately, a team from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center showed in a Nature Medicine paper that leukemia cells were more dependent on METTL3 than normal hematopoietic cells. Samie Jaffrey, an author on the paper and a professor of pharmacology at Weill Cornell, said that the abnormal differentiation seen in leukemia cells was abrogated by only mild inhibition of METTL3important because a complete METTL3 inhibitor delivered systemically would be highly toxic.

The new paper from the Cambridge researchers was therefore a proof-of-concept for Jaffreys approach as well.

I think a lot of other people were cautious because they felt it was a fools errand to go after METTL3, he said. I think this makes the METTL3 target seem much more validated.

Researchers from both groups founded companies to exploit the therapeutic pathway in leukemia. Kouzarides and fellow Cambridge professor Eric Miska co-founded Storm Therapeutics in 2015 to develop first-in-class therapies against RNA epigenetic targets. Jaffrey co-founded Gotham Therapeutics in 2017. Storm has raised 42 million ($59.4 million) seed and Series A rounds, while Gotham raised $54 million in a Series A.

At least one other company appears to be chasing METTL3: Accent Therapeutics, which last year raised a $63 million B round and announced a co-development deal with AstraZeneca utilizing its RNA-modifying protein platform, has presented in vitro data in AML for its inhibitors of METTL3 and METTL14, another m6A writer.

Additional publications have shown more therapeutic possibilities for targeting the m6A pathway, suggesting it may be possible to increase sensitivity to existing therapies in pancreatic and ovarian cancer, for example. m6A methylation has also been linked to a suppressed immune response in infectious diseases like Zika and HIV, and in April a team led by University of California San Diego School of Medicine professor Tariq Rana published in vitro data showing METTL3 inhibition could suppress SARS-CoV-2 replication.

Ranas team has previously shown that the inhibition of ALKBH5, an m6A eraser, can improve the efficacy of cancer immunotherapies in mice, and Rana has spun out ViRx Pharmaceuticals with plans to license intellectual property from the university around RNA therapeutics for broad-spectrum antivirals.

But Storm, Accent and Gotham are starting in AML for a reason. Optimizing compounds for AML is an easier task because unlike other cancers, when you inhibit the METTL3 pathway, you can see the cells differentiating with your eyes, Jaffrey said. In most cancers, you can inhibit METTL3 and they will die but youre inhibiting it to such a degree that probably normal cells will die too. it all comes down to one thing: therapeutic index.

Gotham has identified several solid tumor types with comparable m6A addictions it is looking at closely, he added.

Several other companies are likely targeting different epitranscriptomic targets. Academic work by an Accent scientific cofounder, Chuan He, has focused on YTHDF1, an RNA reader that could function as an immune system control switch for modulating the response to cancer immunotherapy. He is also a chemistry professor at the University of Chicago. Accent is also pursuing ADAR1 inhibitors for cancer.

Silicon Therapeutics, which uses a physics-based approach to drug design for intractable protein targets, is developing an ADAR1 antagonist for cancer. The company said inhibiting ADAR1 can both activate innate antitumor immune cells and directly kill tumors.

Gotham is also looking into additional epitranscriptomic regulators that are much less prevalent than m6A, Jaffrey says, using its screening platform to identify and analyze RNA modifiers.

Kouzarides envisions a lot more opportunities ahead for the burgeoning space. These enzymes can potentially regulate many different processes in many different diseases, he said. He declined to specify which other epitranscriptomic targets Storm is chasing, but the company is currently raising a Series B round to support its anticipated clinical testing for a METTL3 inhibitor in 2022.

Link:
Companies Unlocking a New Class of Cancer Therapies with Sensitive METTL3 Tuning - BioSpace

Prevalence of Plasmodium falciparum isolates lacking the histidine rich protein 2 gene among symptomatic malaria patients in Kwilu Province of the…

Study design and setting

We used secondary data from a prospective health facility-based cross-sectional study conducted on individuals of all ages, seeking healthcare from October to December 2018 in 34 randomly selected health facilities of three health zones in the Kwilu Province (D.R. Congo), Fig.1.

The Kwilu Province is one of 26 provinces of D.R. Congo with an area of 79 906 km2. It is divided into five administrative territories: Bagata (including the city of Bandundu), Bulungu (including the city of Kikwit), Gungu, Idiofa, and Masimanimba [31].

The two selected cities (Bandundu and Kikwit) include three of the 24 health zones of the Kwilu Province [31]. They are the two main cities in the province and bear the highest burden of malaria. pfhrp2 gene deletions were previously reported in this region [14, 32].

Bandundu, the capital city of the Kwilu Province, is located 400km from Kinshasa, the capital of D.R. Congo [33]. Bandundu covers an area of 222 km2 with a population estimated at 950 683 as of 2015 [33]. It has a tropical wet and dry climate with two seasons. Heavy rainfalls and constant heat characterize the rainy season while fewer rainfalls are recorded during the dry season. The average annual temperature is 26.9C [33]. Bandundu City has one semi-urban health zone of the same name and 17 health areas, including 11 urban and six rural.

Kikwit is the second-largest city in Kwilu Province, located in the south-west of D.R. Congo, at 525km from Kinshasa and 400km from Bandundu. It is the main economic city of the province and a commercial hub that provides access to diamond-rich regions of Kasa Province and Angola. Kikwit covers an area of 92 km2 with an estimated population of 1 326 068 as of 2016 [34]. The city has a tropical wet and dry climate with a long rainy season from early September through to the end of May and a short dry season from early June to the end of August. Kikwit City has two urban health zones: Kikwit-Nord and Kikwit-Sud.

The study was approved by the Kwilu Province Division of Health (N ADM/707/01/DPS-KLU/CD/JPBK/632/2018), the Kinshasa School of Public Health Ethical Committee (ESP/CE/015/2019) and the School of Tropical Medicine and Global Health Ethical Review Committee.

The study was first explained to all participants, then written and verbal voluntary informed consent was obtained from all study participants including guardian/parents of non-adult participants.

The study population included individuals of all ages seeking health care in health facilities located in the three Health Zones of Bandundu (one) and Kikwit (two) cities. Health facilities included General Reference Hospitals, Reference Health Centres, and Health Centres. The smallest selection units were individuals attending these health facilities with symptoms suggestive of malaria. The study included all individuals seeking care in the selected health facilities with symptoms suggestive of malaria such as fever, headaches, malaise; during the study period for whom a laboratory test (PfHRP2-RDT and/or microscopic examination) was performed. Individuals who failed to meet the inclusion criteria or did not consent to participate in the study were excluded.

The minimum number of subjects required to enrol in this study was calculated based on a previously reported proportion of pfhrp2 gene deletion in the Kwilu Province (3%) and recommendations from WHO for studies on pfhrp2/3 deletion among symptomatic patients [14, 35]. According to the WHO protocol for estimating pfhrp2/3 deletion prevalence, for an expected prevalence of 3.2%, at least 370 individuals with P. falciparum infection are required per sampling domain [35]. In this study, the sampling domain was the Kwilu province, which included 34 health facilities. The study enrolled a total of 684 patients meeting the inclusion criteria of which 491 were positive for P. falciparum using PCR.

The primary study applied a two-stage random sampling to select health centres. At stage one, 27 health centres were randomly selected among the 62 health centres in the targeted areas. For neighbouring health centres, one health centre was randomly selected out of two. In order to increase the chance of catching individuals not respecting the referral system by directly seeking care in high-level health facilities, four reference health centres and three general reference hospitals from the three health zones were included, bringing the total number of selected health facilities to 34 (27 in Kikwit and seven in Bandundu).

At stage two, individuals attending the selected health facilities with symptoms indicative of malaria were recruited. The lead investigator weighed the number of individuals to recruit per health centre to the average rate of service utilization provided by the National Health Information System.

This study used four groups of variables: sociodemographic, malaria prevention, clinical and biological variables. Plasmodium falciparum HRP2 gene deletion (pfhrp2) was the main outcome variable. Explanatory variables were age, sex, health zones, household size, existence of mosquito breeding sites, LLIN (Long Lasting Insecticidal Net) ownership, use of LLIN, malaria drug intake, malaria clinical features, parasite density, and microscopy result.

Potential participants were introduced to the study by a research assistant. After securing consent/assent from the subjects or their guardians, socio-demographic, malaria prevention and treatment practices, and clinical variables were collected using a pre-tested structured questionnaire. Patients medical records were used to collect data from the physicians or health officers clinical examination.

Heel or finger-prick blood was collected from each individual. Samples for microscopy were prepared using two drops of blood. Then 50l of blood were applied on PfHRP2-RDT, and a few drops were spotted onto Whatman filter paper to prepare dried blood spots (DBS).

The membranes of spent PfHRP2-RDT cassettes and the DBSs were individually stored in plastic bags, sealed with a desiccant at room temperature before being shipped to the Institute of Tropical Medicine in Nagasaki (NEKKEN) where they were refrigerated at 4C.

The CareStart Malaria Pf (HRP2) Ag RDT (Access Bio, Inc., Somerset, New Jersey, USA) was used for the qualitative detection of malaria histidine-rich protein 2 in the whole blood according to the manufacturers instructions [ACCESSBIO, 2018, Somerset, New Jersey, USA]).

The test membrane strip is pre-coated with a P. falciparum HRP2 specific monoclonal antibody as a single line across the test strip. The reported panel detection score is 91.0% at 200 parasites/l with a false positive rate of 0.9% [36, 37]

A team of four medical technologists read the slides in the laboratories of health facilities where samples were collected. When a health facility did not have the necessary equipment to perform the examination, slides were read at the nearest laboratory possessing adequate equipment. For quality assurance, one expert microscopist randomly selected positive and negative slides to cross-check results. In the case results were not concordant, another reading was performed. About five percent of slides went through another quality control in the vector control laboratory of the Kinshasa School of Public Health.

Thick and thin smears were made on the same slide. The part of the slide containing the thin smear was fixed with methanol and dried. Then the whole slide was stained with 10% Giemsas solution for ten minutes and finally washed off with distilled water and air-dried. Stained smears were examined under a microscope for malaria parasite identification. For positive slides, malaria parasites were counted against 200 white blood cells (WBC), and parasite density was calculated based on a total of 8000 WBC/l using the following formula: (Number of Parasites counted8000)/Number of counted WBC.

Parasite density calculation was immediately performed when 100 parasites were counted against 200 WBC. However, in the case that fewer than 100 parasites were counted against 200 WBC, the count continued until 500 WBC.

Genomic DNA was extracted from membranes of spent PfHRP2-RDT cassettes and DBS using the QIAGEN QIAmpDNA extraction kit (company, city, country) according to the manufacturers instructions. We also adapted a previously described method to recover DNA from 197 spent RDTs membranes from Bandundu Health Zone [38].

To confirm P. falciparum infection, we designed specific primers targeting a 226 base pair region of the P. falciparum lactate dehydrogenase (pfldh) gene and performed a real-time PCR assay (Table 1). This assay was also used to ensure there was sufficient parasite DNA quantity in the samples to discriminate P. falciparum negative samples from samples with pfhrp2 gene deletion, as shown in Fig.2.

pfhrp2 gene deletion testing pipeline

Samples were duplicated and loaded in 96-wells plates along with serially diluted positive controls (gDNA from in vitro cultured P. falciparum strain 3D7) (1ng/l, 0.1ng/l, 0.01ng/l, 0.001ng/l), as well as negative controls containing DNA from blood spots prepared from known malaria negative individuals. We repeated the assay for all discordant duplicates and counted three consistent results as the final result.

For detection of the pfhrp2 gene, we performed a nested PCR assay using primers targeting a 228 base pair fragment spanning exon 1, the intron, and a portion of exon 2 of pfhrp2 as previously described (Table 1) [9]. We used a lower elongation temperature (68C) to improve PCR sensitivity, pfhrp2 being AT-rich, and increased the number of cycles to 40. We used genomic DNA from Dd2 (pfhrp2 negative) and 3D7 (pfhrp2 positive) as controls for all assays.

We repeated the nested PCR for all negative results. In the case of discordant results, we performed the amplification a third time and counted two consistent results as the final result.

Reaction components for both real-time and nested PCR are summarized in Table 1.

PCR amplicons were separated by electrophoresis on a 2% agarose gel stained with Gel Red Nucleic Acid Stain 10 000in water. A total of 12l of PCR amplicons (6l) and loading dye (6l) were loaded onto the gel, which was run for 35min at 100V and observed under UV light. A 500g/ml Gene Ruler 100bp DNA Ladder (BioLabsinc, Ipswich, USA) was loaded onto the same gel to determine the sizes of the resolved fragments.

Data were entered and analyzed using STATA15 (StataCorp LLC, Lakeway, Texas, USA). Tables have been used to describe categorical variables. Continuous variables have been summarized using median and interquartile ranges. Proportions have been used to summarize categorical variables.

Fischers exact test (for categorical variables) and the KruskalWallis test (for non-normally distributed continuous variables) were applied to look for associations between potential explanatory variables and the main outcome (pfhrp2 gene deletion). We computed the 95% Confidence Interval (95% CI) for the prevalence of pfhrp2 gene deletion. We considered a P-value less than 0.05 statistically significant.

Read more:
Prevalence of Plasmodium falciparum isolates lacking the histidine rich protein 2 gene among symptomatic malaria patients in Kwilu Province of the...

QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) – Business Wire

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Miratis investigational, highly selective and potent oral small molecule inhibitor of KRASG12C.

The agreement initially focuses on a companion diagnostic test for non-small cell lung cancer (NSCLC), and allows for further development of tests for other Mirati oncology programs.

The planned companion diagnostic would expand upon QIAGENs therascreen KRAS testing portfolio based on real-time qualitative PCR for the QIAGEN Rotor-Gene Q MDx instrument, a member of the modular QIAsymphony family of automation solutions, and builds upon the Companys nearly decade of experience in KRAS companion diagnostic test development and commercialization. QIAGEN and Mirati have previously partnered for the development of a companion diagnostic.

We are pleased Mirati recognizes the success of QIAGENs therascreen platform and continues to partner with us to develop a tissue-based companion diagnostic to identify patients who may benefit from adagrasib. QIAGENs experience and expertise in developing diagnostic solutions for Precision Medicine are well-suited to evaluate patients with non-small cell lung cancer, said Jean-Pascal Viola, Senior Vice President and Head of QIAGENs Molecular Diagnostics Business Area. Our collaboration with Mirati is a demonstration of QIAGENs capabilities as a preferred partner of pharmaceutical and biotech companies for the creation of companion diagnostics.

The therascreen-based companion diagnostic detects KRASG12C, a genetic mutation that is one of the most common KRAS alterations linked to cancer. The RAS gene family is the most frequently mutated oncogene in human cancer, with KRAS being the most prevalent driver mutation in NSCLC.

QIAGEN is a pioneer in Precision Medicine and the global leader in collaborations with pharmaceutical and biotechnology companies to co-develop companion diagnostics, which detect clinically relevant genetic abnormalities to provide insights that guide clinical decision-making in diseases such as cancer. QIAGEN has an unmatched depth and breadth of technologies from next-generation sequencing (NGS) to polymerase chain reaction (PCR) for companion diagnostic development. QIAGEN has nine PCR based companion diagnostics that are FDA approved, including therascreen EGFR for non-small cell lung cancer, therascreen KRAS for colorectal cancer, therascreen FGFR for urothelial cancer, therascreen PIK3CA for breast cancer based on tissue or plasma samples and the therascreen BRAF kit for colorectal cancer.

Currently, QIAGEN is working under master collaboration agreements with more than 25 companies to develop and commercialize companion diagnostic tests for their drug candidates a deep pipeline of potential future products to advance Precision Medicine for the benefit of patients. QIAGEN is partnering with Illumina to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2020, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Category: Corporate

Go here to see the original:
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) - Business Wire

STAT+ Conversations: A discussion on health disparities in colorectal cancer with Dr. Fola May – STAT – STAT

Editors note: A recording of the conversation is embedded below.

Every week, STAT+ subscribers get access to exclusive content with biotech, Pharma, and health tech leaders. This week, STAT general assignment reporter and associate editorial director of events Nicholas St. Fleur will be joined by Dr. Fola P. May, assistant professor of medicine at UCLA. They will be discussing health disparities in colorectal cancer and why 45 is the new 50 for screening age, and of course be taking your questions live.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Read the original:
STAT+ Conversations: A discussion on health disparities in colorectal cancer with Dr. Fola May - STAT - STAT

Utica man producing film about the history of radio – The Oakland Press

Decades before Spotify, Pandora, and even satellite radio, terrestrial (land-based) AM and FM radio reigned supreme. Many listeners, including Utica resident Ron Robinson, idolized the disc jockeys just as much as the artists they played.

Robinson, 51, is working on a documentary film entitled Radio Dayz The Movie, which focuses on the history of radio, including the early days of Detroit radio. (The film) tells the story of radio through the people who worked in radio, he said.

Robinson interviewed several well-known radio personalities such as Paul W. Smith, Dick Purtain, Fred Jacobs, Dick Kernen, and more for the film. Robinson, who worked for WJR for 20 years before starting his own production company, has several connections in the industry. He started interviewing for the documentary in 2013.

Most people think of radio, they think of New York, California, and Chicago, and rightfully so. But, Detroit has been an important and ground-breaking city for the medium of radio, Robinson said.

The documentary is a chronological look at the history of radio, starting with the first radio stations. It also takes aim at the first radio celebrity, Fr. Charles Coughlin. The Detroit-area priest took to the airways in the 1920s and eventually garnered an audience of 30 million to his weekly radio show. Coughlin would later become a polarizing figure as World War II approached. Hes on the wrong side of history, if you will, Robinson said.

Other notable glimpses into radios history are also featured in the film, including President Franklin D. Roosevelts Fireside Chats and the healing effect these popular radio segments would have on a nation crippled by The Great Depression and the war.

Then I go and talk about the 1940s and 1950s and what Elvis and the Beatles mean to radio. Theres a part about how radio changed when TV became the mainstay in everybodys house, Robinson said.

Robinsons podcast Radio Dayz! delves into the history of radio as well and has served as a promotional piece for the documentary. What we do is let listeners in on what happened behind the scenes in radio, he said. Most people know their (radio personalities) voices, but not their story.

The documentary has served as a labor of love for Robinson. And although it is not yet complete, he plans to wrap up the project soon. He had hoped to finish in time for WWJs 100th anniversary but was unable to interview key radio personalities due to COVID-19 restrictions.

He said it is important to preserve radios history for future generations, especially today when few people even own a radio. There are so many stories people dont know and I want to share that with people because I think they will be better off and more enriched and appreciate where this country has been, he said.

When the film is complete, possibly later this year, Robinson hopes to have it available to stream.

This is Robinsons fourth documentary film. He also produced It Takes a Village, Networking, Your Business The Movie, and If You Build It, They Will Come. The later film focuses on the development of Jimmy Johns Field in Utica.

In addition to making documentary films, Robinson is a photographer and aerial/drone media pilot. His production company, Ron Robinson Studios, also offers video marketing services for businesses.

Original post:

Utica man producing film about the history of radio - The Oakland Press

Remember to say thank you before it is too late – The Daily Times

Living most of my life in the Kings Creek area, I cant even guess how many times Ive driven by the baseball fields on Kings Creek Road in Weirton. During the warmer weather, its common to see someone on a tractor cutting the grass on the ballfields or dragging the infields. For so many years, that person was either Joe Tunno or Tim Welch, both of whom have spent countless hours of their lives quietly and unassumingly serving the youth of Weirton through the Weirton Baseball Association.

After hearing a few weeks ago about Welchs death, one of my first thoughts was that I never stopped just to tell Tim thank you for taking care of the fields. I took it for granted that Tim would do what so many of the rest of us cant or choose not to do. Tim never wanted anything in return for the thousands of hours he volunteered at the ballfields. Im not even sure if being thanked was important to him. I think not otherwise, he wouldnt have done so much for the kids in exchange for the little thanks he likely got. Tim began coaching my brother Toms Babe Ruth team in 1980 and during the next 30 years continued his unwavering service to the Weirton Baseball Association.

Tims gift of his time and talents didnt just benefit the WBA he also was involved for even more years with the Weirton Termite Basketball Association at the Millsop Community Center (along with Ron Greer, another gentleman whose volunteerism knew no bounds.)

For years, these two men kept the league together, coaching, getting sponsors, handling the draft, scheduling games, training young referees and dealing with emotional parents, among other things. It would not be uncommon for Tim to grab a whistle and officiate games when young referees failed to show up or were busy with another game.

Greer still is running the league after 50 years of service I cant imagine how many pounds of fish Ron has cooked while also volunteering at the local Lenten fish fries during the years or how many hours he has served the Weirton Jaycees. Among other causes, Ron also has been serving our special needs citizens as a board member and officer at the Hancock County Sheltered Workshop for many years.

I will make it a priority to reach out to Greer and Tunno and thank them for the good they do for the community. I could kick myself in the butt for not taking the time to thank Welch he was a quiet, kind, humble and unassuming man who, nevertheless, deserved my thanks.

We have been blessed in Weirton with individuals who have given their time and talents for the benefit of the youth in our community. As a youngster, I had the honor of playing basketball at St. Joseph for Jim Klash, who coached at the school for more than 30 years. I didnt know until after he passed away that Klash was a parishioner of St. Pauls, St. Joes rival in youth basketball back in the day. Klash also was one of the founding members of the Weirton Baseball Association Complex. He gave me one of my first jobs as an umpire. I hope the Weirton community and St. Joes never forget them.

I know Im forgetting or have failed to mention many men and women who have volunteered countless hours in our community during the years. I intend no disrespect. You know who they are. They were our coaches, league presidents and concession stand workers they opened, cleaned and closed the gyms where your kids and mine played ball, or they worked on the ballfields after a heavy Saturday morning rain so your kids could play their baseball game.

The next time you see them, go and tell them thanks for all they do or what they have done during the years before that opportunity passes you by. I certainly will. I missed that opportunity with Tim Welch and I regret my omission.

Weirton and its children are so very lucky to have such committed and generous volunteers, like Tim Welch, and we will miss them dearly and their selfless contributions to our community.

Thank you, Tim.

(McCune is a resident of Weirton. Tim Welch died April 18 at the age of 61.)

Today's breaking news and more in your inbox

The rest is here:

Remember to say thank you before it is too late - The Daily Times

Defence spending and ADF readiness need to match the risk of conflict | The Strategist – The Strategist

In last weeks expansionary budget, one area that felt a bit underdone was defence. Here, the government delivered what it promised 12 months ago: $44.6 billion, an increase over last years budget of 4.1% in real terms.

At any time in the last 25 years a defence budget growing at that level would have been welcome. But now Australia and the wider region faces the direst strategic outlook since perhaps the end of World War II.

Its clear that Scott Morison and his ministers understand that the region is facing a crisis brought on by an increasingly bellicose Chinese Communist Party. Taiwan is the immediate flashpoint and the level of risk will peak in perhaps four to five years time. In that period, according to the United States Defense Department, the Peoples Liberation Army will gain a strong military edge over the Taiwan Strait in air power, missiles and ships.

Would Xi Jinping risk his own future, as well as that of the CCP, to stage an attack on Taiwan? Xi has learned to turn risky situations to his advantage. In the illegal annexation of the South China Sea, in cyber spying and intellectual property theft, the imposition of communist authority in Hong Kong, and in the economic coercion of Australia, Xi took significant risks to strengthen his rule and largely got away with them.

He will apply the same strategy to Taiwan, using all means short of war and indeed some measures that cross that offensive line right up to the limits of US tolerance.

Ill come to what this might mean for Australia and for the defence budget soon, but first consider a remarkable phenomenon, which is the ability of so many in Australia to deny what is obvious about Beijings intentions.

Writing in the Australian Financial Review, former foreign minister Gareth Evans judged that no Chinese political or military preparations suggest an invasion is remotely imminent. That is an astonishing misjudgement.

On 24 April Xi presided over a ceremony commissioning three major warships for Chinas southern fleet. Communist party newspaper the Global Times declared: These vessels will play important roles in solving questions in places like the island of Taiwan and the South China Sea.

Hardly a day goes by without PLA aircraft, often in large numbers, encroaching Taiwanese airspace. CCP rhetoric about taking Taiwan by force if necessary is increasingly being used in speeches and editorials.

Xi will hope this show of strength will deter the US and the allies from stepping in and that his aims can be realised short of war, but we all need to understand that the risk of conflict is sharply growing.

In Washington last Thursday, US Secretary of State Antony Blinken and Foreign Minister Marise Payne held talks and gave a press conference, underlining the closeness of the alliance relationship.

The secretary of state stressed the Biden administrations interest in reaffirming and revitalizing Americas alliances and partnerships and, in the 70th year of the ANZUS Treaty, finding ways for the alliance to evolve to meet the challenges we face.

Blinken said the US will not leave Australia alone on the field, or maybe I should say alone on the pitch, in the face of economic coercion by China. Thats what allies do. We have each others backs.

Understand that the US has every expectation that the requirement for support runs in both directions. Washington wants Australia to do more, is telling us that the alliance needs to be revitalised and that challenges will be faced together.

This will include working out how to jointly respond to CCP belligerence over Taiwan, which wasnt mentioned once in the BlinkenPayne press conference. Sometimes you can judge the significance of an issue by the way it isnt mentioned publicly.

Back to the defence budget. The Morrison government has delivered everything that it has promised to do in the 2016 defence white paper and more, including two additional P-8 Poseidon maritime surveillance and anti-submarine warfare aircraft and four extra CH-47 Chinook heavy lift helicopters. There is also an accelerated plan to establish a missile manufacturing capability in Australia.

While these are positive steps, the uncomfortable truth is that the bulk of the $270 billion allocated over the coming decade to build ships, submarines and other military equipment will only come into service well after the riskiest period for Taiwan.

Defence Minister Peter Duttons most pressing challenge is to strengthen the Australian Defence Force in the shortest time frame possible. An immediate candidate will be to move quickly on the life extension and upgrade program for the Collins submarines. The government should also explore options to add yet more P-8s to the current 14 airframes but there are limits to what can be done quickly.

A faster way to strengthen deterrence would be to re-open a discussion with the US about increasing the US Marine Corps presence in northern Australia and getting some US Navy ships operating out of our west coast base, HMAS Stirling.

When the US marine presence was being negotiated a decade ago, the initial American offer was to deploy a 7,500-strong Marine AirGround Task Force. The Australian government of the day baulked, and instead we had a decade-long slow growth to the current annual contingent of 2,500.

A larger marine presence ultimately hinges on access to a port facility. Consider the thought that if Beijing wanted to slow down the growth of AustraliaUS defence cooperation in the Top End a clever way to do it would be to take control of the areas most viable port, which is exactly what happened in 2015 when Darwin Port was leased to a Chinese company for 99 years.

The world has fundamentally changed since then. Now, the opportunity to strengthen a shared US and Australian deterrent posture in the Indo-Pacific needs to be urgently reconsidered.

A conflict over Taiwan would be a disaster for all concerned, but disastrous conflicts happen all the time. At this point the best hope to keep the peace is to change Xis calculation about the level of risk China would face if it initiated such a crisis.

The only short-term way to strengthening deterrence is by lifting the defence readiness of democracies. If US President Joe Biden does visit Australia for the ANZUS anniversary, you can be assured this will be the number one item on his agenda.

Original post:

Defence spending and ADF readiness need to match the risk of conflict | The Strategist - The Strategist

What’s Missing From the Conversation About Work-Life Balance – Entrepreneur

Achieving a work-life balance starts with you.

Stay informed and join our daily newsletter now!

May15, 20214 min read

Opinions expressed by Entrepreneur contributors are their own.

Youve received the standard advice about setting boundaries with the hours you work if youre now (or have always) worked from home.Youve read that you should focus on tasks more intentionally by using software that blocks social media and email notifications.You may have even experienced work-life balance for a while.

However, whats missing from the conversation about work-life balance is the need for self-prioritization in goal setting, work, productivity and the desire to optimize ones life. Here are three reasons why making yourself a priority is the key and foundation to achieving work-life balance.

Related:The Secret Cause of Burnout and How Entrepreneurs Can Avoid It

Do you wake up, look at your to-do listand verbally cringe? Chances are, most of what you do each day is the same, and the routine is draining you mentally, and by extension, physically.

When you spend day in and day out grinding with no time allotted for fun and all the personal goals youd like to accomplish it leads to frustration, bitterness and burnout. You arent excited to work, which diminishes your energy and motivation. The resulting burnout decreases productivity and amplifies excuses.

Work-life balance has to be about balance. But more than figuring out a schedule that works for you, youll need to incorporate plenty of "youtime." Your schedule should include moments when you work on hobbies, do fun things and focus on personal optimization.

If youre feeling stressed and mentally exhausted when you think about work and your goals, its time to take a step back and ask yourself when was the last time you did somethingjust for you?Youll be more productive and develop the ability to work more intentionally when your life doesnt feel like a burden.

Related:Building a Business Shouldn't Require You Stop Having a Life

When youre good at what you do, it can be easy to let that become part of your identity. Its not uncommon for someone whos been the boss at a job or business to have readjustment challenges to changes in their work situation millions of Americansexperienced just that over the past year.

If you tie your identity to your work, youll lose balance when life circumstances becomeunpredictable. Work-life balance starts with you being secure in your non-work priorities and unattachment to circumstances you cant control.

There are so many experiences of life and moments to be lived beyond work. Work helps you build the financial freedom to experience life, but dont let it overtake the balance and tie your beliefs about yourself to circumstances that dont have to define you.

Whether you realize it or not, you are the most significant project you will ever pursue. When you make your optimization a priority, you will be more productive. When youre excited about life and the opportunity to work, youll reduce stress and burnout.

Start with making yourself the priority. Family, friends, coworkers, clients, and anyone else that demands your time and energy should see and respect your boundaries.

Spend time each day with one task, goalor fun experience thats just for you. If you can do that at the start of your day, youll train your mind to understand that youre the main priority. Do this over time, and youll wake up excited for what the day will hold.

As you build the self-prioritization muscle and develop healthy self-care habits, youll achieve a work-life balance more sustainably.

Related:Teach Others How to Treat Your Business

Read more:

What's Missing From the Conversation About Work-Life Balance - Entrepreneur

Global Reishi Mushroom Extract Market is slated to grow rapidly in the coming years: Vitacost,Swanson,Life Extension KSU | The Sentinel Newspaper -…

Most recent Research Report onReishi Mushroom Extract Market[ Browse Complete Summary Of This Report | FREE Sample PDF ]features a detailed analysis of key segmentation of the Reishi Mushroom Extract Market with valuable information and data[By Product Type(Powder, Liquid), By Application(Health Care Products, Essential Oil, Others) and By Region(North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)]. The revenue share combined with insightful forecasts for the significant sections and the other huge sub-segments has been broke down in detail in the Reishi Mushroom Extract market report. This exploration report catches a few attributes of organizations, for example, request and overview of the products or services and 360-degree outlook of the serious scene of the worldwide Reishi Mushroom Extract Market.The report forecast worldwide Reishi Mushroom Extract market development to arrive at (XXX) Million USD in 2021 with a substantial CAGR (XX%) esteem during the time of 2021-2028.

Key Offerings:

Market Forecast by Size and Revenue | 20212028 Market Segmentation A total analysis by types, product, applications, end-client, portions, and geology Market Dynamics development drivers, Leading patterns, restrictions, and speculation opportunities Competitive scenario Top significant vendors and other noticeable vendors

For Right Perspective & Competitive Insights on Reishi Mushroom Extract Market, Request for a Sample PDF:https://www.industryandresearch.com/report/GlobalUSA-Reishi-Mushroom-Extract-Market-Report-Insight-Key-Research-Findings-Competative-Landscape-and-Forecast-20212028/245098#samplereport

The expansion of various progressed innovative, methodological, pragmatic, and hypothetical concepts helps the Reishi Mushroom Extract market surpass all the worldwide improvement viewpoints and possibilities. The Reishi Mushroom Extract market report has all the development factors, market interest chain, rigid measures, Reishi Mushroom Extract market players, Reishi Mushroom Extract market share of the overall industry, and other fundamental factors all referenced in a simple arrangement. The Reishi Mushroom Extract market report has every one of the subtleties explaining the current components, developments, and advances are determined to sum things up. The proportion of organic market alongside the financial ups and down is given in the Reishi Mushroom Extract market report in a perfectly clear and fresh manner. The relevant Reishi Mushroom Extract market report additionally has development elements, segment, end clients, product types, provincial bifurcations, and more gave in an edible way. The Reishi Mushroom Extract market is divided dependent on dependability, quality, and worldwide Reishi Mushroom Extract market analysis. The in-depth data about the Reishi Mushroom Extract markets social and financial status is included connection to the scientific methods and current business trends.

Reishi Mushroom Extract Market Segmentation:

Regional Analysis of Global Reishi Mushroom Extract Market:

All the provincial division has been examined dependent on later and future patterns, and the market is estimated all through the forecast period. The district and nations shrouded in the local analysis of the Reishi Mushroom Extract market report are:

-North America(U.S., Canada, Mexico)

-Europe(Germany, U.K., France, Italy, Russia, Spain, etc.)

-Asia-Pacific(China, India, Japan, Southeast Asia, etc.)

-South America(Brazil, Argentina, etc.)

-Middle East & Africa(Saudi Arabia, South Africa, etc.)

Key Questions Answered by Reishi Mushroom Extract Market Report:

What was the Reishi Mushroom Extract Market size in 2019 and 2020; what are the assessed development patterns and market estimate (2021-2028). What will be the CAGR of Reishi Mushroom Extract Market during the forecast time (2021-2028)? Which portions (product type/applications/end-client) were generally appealing for interests in 2019? How these segments are relied upon to develop during the estimate time frame (2021-2028). Which producer/seller/major parts in the Reishi Mushroom Extract Market was the market chief in 2020? Overview of the current product portfolio, products in the pipeline, and strategic drives taken by key merchants in the Reishi Mushroom Extract market.

{{Inquire/Speak To Expert for Further Detailed Information About Reishi Mushroom Extract Report}}

Some Point from Table of Content:

Market Overview:It incorporates six parts, research scope, significant makers covered, market sections by type, Reishi Mushroom Extract market portions by application, study objectives, and years considered.

Market Landscape:Here, the opposition in the Worldwide Reishi Mushroom Extract Market is broke down, by value, income, deals, and portion of the overall industry by organization, market rate, cutthroat circumstances Landscape, and most recent patterns, consolidation, development, securing, and market shares of top organizations.

Profiles of Manufacturers:Here, driving players of the worldwide Reishi Mushroom Extract market are examined dependent on deals territory, key products, margin, income, price, and creation.

Market Status and Outlook by Region:In this part, the report examines about gross margin, deals, revenue, creation, market share, CAGR, and market size by area. Here, the worldwide Reishi Mushroom Extract Market is profoundly examined based on locales and nations like North America, Europe, China, India, Japan, and the MEA.

Application or End User:This segment of the analysis study shows how unique end-client/application portions add to the worldwide Reishi Mushroom Extract Market.

Market Forecast: Production Side:In this piece of the report, the creators have zeroed in on creation and creation esteem conjecture, key makers estimate, and creation and creation esteem figure by type.

Analysis Findings and Conclusion:This is one of the last areas of the report where the discoveries of the experts and the finish of the research study are given.

TOC Continued!https://www.industryandresearch.com/report/GlobalUSA-Reishi-Mushroom-Extract-Market-Report-Insight-Key-Research-Findings-Competative-Landscape-and-Forecast-20212028/245098#requesttoc

The Reishi Mushroom Extract market report conveys all the data be it about the figure, significant players, deals elements, monetary changes, and flow benefits solely after an exhaustive analysis and exploration. The Reishi Mushroom Extract market changes, limiting components, revenue supporters, and inventive patterns significantly affect the development and advancement of the worldwide Reishi Mushroom Extract market and consequently, the informative reports like this assist well with comprehension and reason out the Reishi Mushroom Extract markets prominence

Email:sales@industryandresearch.comWebsite:www.industryandresearch.com

Original post:

Global Reishi Mushroom Extract Market is slated to grow rapidly in the coming years: Vitacost,Swanson,Life Extension KSU | The Sentinel Newspaper -...

Apeel Acquires Imaging Technology to Unlock The Insights In Every Bite of Fruit – PRNewswire

SANTA BARBARA, Calif., May 11, 2021 /PRNewswire/ -- Apeel today announced its acquisition of ImpactVision for an undisclosed amount. ImpactVision's hyperspectral imaging technology is soon to be integrated into Apeel application systems at supplier locations around the world adding a new layer of insights to help fresh food suppliers and retailers further reduce food waste.Apeel's new imaging technology enables suppliers to see inside and understand the interior quality of fresh produce by collecting quantifiable data on stage of ripeness, freshness, nutritional density, and other indicators of quality. This marks Apeel's first acquisition and a major step toward quantifying and digitizing produce quality data, with the goal of democratizing this new information for the benefit of Apeel's partners and the global food system as a whole.

"Our journey began with Apeel's plant-based protection - an invisible 'peel' that addressesthe challenge of global food waste by bringing more time to fresh produce before it spoils. Now,we're expanding our technology to bring to light the previously invisible characteristics of produce, including internal quality, phytonutrient content, and environmental impact," said James Rogers, CEO of Apeel. "Using the insights enabled by Apeel's imaging technology, our partners willeffectively be able to 'see' inside of every fruit and vegetable, quantifying quality as never before, so that the distribution of fresh food can be optimized. For our partners, this will mean less wasteand an immediate bottom-line improvement, and ultimately, the ability to one day differentiateproduce by making freshness and nutritional content 'visible' to the consumer."

Apeel's plant-based protection that doubles the shelf life of produce is currently applied to fruitsand vegetables via application systems throughout packing houses and distribution centersacross North America, South America and Europe. Apeel's new imaging technology will be addedto these systems to collect data-rich images as produce travels along packing house conveyance lines. Acquired images will then be processed through machine learning models that can identify unique visual cues that relate to freshness, degree of maturity, phytonutrient content, and other aspects of fruit quality.

"ImpactVision's technology can predict internal quality of food products from hyperspectral images. When this ability to 'see beyond the borders of human vision' is combined with Apeel'sshelf-life extension technology, the potential to fundamentally transform produce supply chains to reduce post-harvest loss, optimize distribution and lengthen shelf-life is enormous," said AbiRamanan, Founder of ImpactVision.

With Apeel's continued expansion into new produce categories and geographies, the company ispoised to capture category-wide datasets across a previously fractured and data-poor landscape,which in turn will help shape new efficiencies and benefits that span across global fresh fruit andvegetable supply chains. Given that 40% of the food grown globally goes to waste, this morerobust and holistic understanding of produce quality will allow fresh food suppliers to optimizedistribution, thereby reducing food waste, and maximizing the quality that reaches consumers.

For example, suppliers can now know the exact ripening window for each piece of fruit to thensort and ship to geographical locations that will ensure retailers are getting the highest qualityproduce.

Today, Apeel has 30 supplier integrations on three continents with plans to double that numberby the end of 2021. With its imaging technology and positioning in the fresh food supply chain,Apeel is on a path to developing the largest and most comprehensive database of objective freshproduce insights for the global food industry.

Please visit Apeel's website for more information about Apeel plant-based protection andtechnologies.

ABOUT APEEL

Apeel is on a mission to create a more sustainable global food system by using the power ofnature to enable longer-lasting produce that fights food waste from farm to kitchen. Apeel producelasts 2x longer thanks to its plant-based protection made from materials found in the skins, peelsand seeds of all fruits and vegetables. Apeel's protective extra "peel" slows the water loss andoxidation that cause produce to go bad, and is the only proven end-to-end solution for maintaining freshness. Available for organic and conventionally grown produce, Apeel is expanding into anever-growing number of categories and markets. Good for consumers and the planet, Apeelreduces environmental impacts and gives everyone throughout the supply chainfrom growersto retailers to consumersmore time to enjoy fresh produce. Farmers can sell more of what theygrow and people can consume more of what they buy, creating a healthier planet and greaterabundance for all. Apeel is Food Gone Good.

Apeel is a trademark/registered trademark of Apeel Technology, Inc. in the United States, theEuropean Union, and other jurisdictions. To learn more, visit apeel.com.

CONTACT: [emailprotected]

SOURCE Apeel

https://www.apeel.com/

Read more from the original source:

Apeel Acquires Imaging Technology to Unlock The Insights In Every Bite of Fruit - PRNewswire

Chris Berman signs multiyear extension with ESPN – ESPN

Chris Berman will continue to host NFL PrimeTime after agreeing to a new contract with ESPN.

The multiyear agreement was announced on Berman's 66th birthday Monday.

"We've been working on it for a while, and this was the perfect time to do it," Berman said during a telephone interview. "ESPN has been almost two-thirds of my life. I'm honored that what I do still works."

Berman has been an integral part of ESPN throughout its history after joining the network a month after its launch in September 1979. Besides being one of the original SportsCenter anchors, he also has been a key part of the network's NFL and baseball coverage.

He hosted NFL PrimeTime with Tom Jackson from 1987 to 2005 on ESPN and then starting again in 2019 when it returned on the ESPN+ streaming service. Berman -- who also hosted NFL Countdown from 1985 to 2016 -- teamed up with Booger McFarland for PrimeTime last year when Jackson could not travel due to the coronavirus pandemic.

Berman approached ESPN President Jimmy Pitaro when ESPN+ started about the possibility of reviving PrimeTime. Berman said seeing the success of PrimeTime on the streaming service has mirrored watching the growth of ESPN.

"The fact that I will get to do it again this season is something I have enjoyed the most," he said. "I love being able to help build another entity with it this time being in the streaming world."

Berman said it remains to be determined who will join him on PrimeTime during the coming season.

Berman was the 2010 recipient of the Pro Football Hall of Fame's Pete Rozelle Radio-Television Award and has been the master of ceremonies for the Hall's induction ceremony since 1999.

"Quite simply, Chris Berman has personified ESPN's success for more than four decades," Norby Williamson, ESPN's executive vice president and executive editor, said in a statement. "Fans respond to his authentic love of sports, his ability to savor and capture the big moments, and his on-air style that reminds us how live games can truly be equal parts essential and fun. We are delighted Boomer's magical ride at ESPN will continue for years to come."

Read the original post:

Chris Berman signs multiyear extension with ESPN - ESPN

North Country summer camps coming back to life and filling up fast – North Country Public Radio

May 11, 2021

Canoeing at 4-H Camp Overlook in Malone, NY. 2019. Photo courtesy of 4-H Camp Overlook and Cornell Copperative Extension.

This year, New York summer camps are all about cohorts, pods, and bubbles. Not soap bubbles, said Doug Fuhrman, but a social bubble to try and keep COVID-19 out, "...theres a lot of talk in the camping world about bubbles, and creating a bubble that you can be safe within.

Campers at North Country Camps in Keeseville, NY. Photo courtesy of North Country Camps.

Fuhrman directs Camp Lincoln at North Country Camps in Keeseville. Its a two month long residential camp, with about 250 campers and staff. While Fuhrman says he doesn't believe that any camp can create a perfect bubble," he said creating the best one possible is still valuable. To create theirs at North Country Camps, the whole staff will be vaccinated. Theyll be testing kids at camp, and all the kids will be arriving at the same time, negative COVID-19 test in hand.

Having everyone come at once in a very controlled fashion, and only having kids leave after that really limits your exposure for the rest of the summer, said Furman.

A backpacking trip at North Country Camps in Keeseville, NY. Photo courtesy of North Country Camps.

Even with new rules and restrictions, Fuhrman and other camp directors report camp interest and enrollment are high.

Stephen Hoitt is the Director of the Rochester-based Seneca Waterways Council, part of Boy Scouts of America. He says just their deposits have already exceeded enrollment from before the pandemic, in 2019.

Which is crazy, we did not expect that to happen, we figured wed land somewhere between 2020 and 2019, and to already be there in deposits is super exciting, said Hoitt.

Hoitts organization runs three summer camp programs in New York, the largest of which is Massawepie, outside of Tupper Lake. Hoitt says things will have to be different this summer at all their camps to be safe.

Archery at Massawepie Scout Camps, Seneca Waterways Councils traditional Scout summer camp. Photo courtesy of Seneca Waterways Council.

They're changing their dining services from family style to single serving, and setting up circus tents for more covered seating. Certain close-contact games will probably be getting the ax, like the beloved Watermelon Scramble, a game played in shallow water with an olive oil greased watermelon.

They take a watermelon and rub it down with olive oil, so its slippery, and theyll put it in the water, and the kids got to push it into a goal on the opposite side...and the kids love to do it, but it's in a condensed area, so that will probably not happen this year.

Its a probably because while NY State gave summer camps the green light back in February, they still havent released official guidelines. Camps are making their best guesses off of CDC And American Camp Association recommendations.

But there are bigger questions than greased watermelons that need to be answered. Like capacity.

Swimming at 4-H Camp Overlook in Malone, NY. 2019. Photo courtesy of 4-H Camp Overlook and Cornell Copperative Extension.

Capacity is a huge question mark. Will camps be allowed to operate at 100% capacity? If not, who will they have to turn away?

To be safe, 4-H Camp Overlook, a one week residential camp just outside Malone, decided to limit their enrollment, explained Director Casey Sukemore: Weve gone with the conservative route, and done a 50% capacity in cabin. We really didnt want to disappoint families and tell them no. Wed rather open up and tell families yes.

Theyve already got waitlists for most of the summer's sessions.

Camp Overlook, like many others camps, will be using a pod structure to limit kids' overall interactions with the larger group. Camp Overlook plans to have 20 or so kids going through the week together. Theyre also doing as much outdoors as possible, including all meals, and even scheduling things like shower times.

Its looking very different this year," laughed Sukemore, "but I think it will be a really successful summer.

Waterfront at Massawepie Scout Camps, Seneca Waterways Councils traditional Scout summer camp. Photo courtesy of Seneca Waterways Council.

For Sukemore, a successful summer will be one where kids can forget the coronavirus pandemic altogether.

Ive heard from families so much this year that campers really need camp," said Sukemore. "So my hope is that they come this summer, and they don't even notice that anything is different!

Camp directors like Sukemore will be behind the scenes, sanitizing arrows and scheduling shower times, trying to pull off that normal summer camp experience.

In the woods at 4-H Camp Overlook in Malone, NY. 2019. Photo courtesy of 4-H Camp Overlook and Cornell Copperative Extension.

Originally posted here:

North Country summer camps coming back to life and filling up fast - North Country Public Radio

Is Radhe-Your Most Wanted Bhai an Extension of Salman Khans Real Life Personality? – News18

Bollywood superstar Salman Khan will be back on our screens, both big and small, after almost two years with Radhe: Your Most Wanted Bhai. The film, which will be Salmans Eid gift to his fans, will release in a hybrid model. The film will be released in theatres, on ZEE5 with ZEEs pay per view service ZEEPlex, and on all leading DTH operators like Dish, D2H, Tata Sky and Airtel Digital TV.

Radhe is Salman Khans third collaboration with Prabhudeva, which means we can expect the film to have elements of their previous hit projects together, namely Wanted and Dabangg 3. In Radhe, Salman plays an undercover cop trying to bring down a drug nexus, a fitting tribute to the other two films.

The trailer of the film was released last month and it promised a wild-ride from start to finish. Not only were there elaborate fight sequences in slow motion. There were also Salman Khan special one-liners. The other characters of the film were also as interesting as Salmans Radhe. Randeep Hoodas antagonist looked psychopathic and sleek. Jackie Shroff, who plays a senior police officer was quirky, to say the least. He also was the elder brother to Disha Patanis character, who looked stunning and needed saving from the hero. In a nutshell, Radhe promises every element of a typical Salman Khan model.

In fact, it can be argued that Radhe is an extension of Salman Khans larger-than-life personality, which he has so carefully curated. Salman Khans image as a superstar solidified in 2009 when he starred in Wanted. While he had played a cop before, this was his first venture where he played one with a flamboyant personality. In a way, Wanted was a precedent for super-cop films such as Salmans own Dabangg franchise, and Rohit Shettys cop universe. Wanted was Salmans first film to enter the 100 crore club. Every film Salman has ever acted in since then, has managed to earn at least 100 crores in the box office.

Salman Khan has also always benefited from roles in which he plays some kind of an authority figure- a policeman, a soldier or an intelligence officer. Of course, there are always some films like Bajrangi Bhaijaan or a Sultan, which explore his range more than others. However, Salman Khan fans are always more comfortable in watching him beating up a 100 baddies. And by the looks of it, Salman is comfortable in making those films, too.

Take the Dabangg franchise. The first film, which came out in 2010 saw Salman Khan as Chulbul Pandey, a cop who doesnt hesitate to break the rules to teach the villains a lesson, wears his sunglasses at the back of his head, passionately pursues his lady love and breaks out into dance moves every so often. The first film was extremely entertaining, with one-liners that people still remember well. The success of Dabangg prompted two sequels, which werent half as good, but successful, nonetheless.

Even with a comparatively serious action thriller like Ek Tha Tiger, Salman Khan has managed to churn out a franchise which will be successful no matter who directs it.

On the other hand, even when Salman plays a criminal or a con-man, people love to see it because it is another way the actor can display his machismo. A film like Kick, where Salman plays a thief with a heart of gold, works because of the action sequences, the bike chases and the dialogues. As long as his character is a mighty action-hero, fans are satisfied.

This is directly linked to how Salman chooses to carry himself in his personal life. His characters usually dress like him, they walk and talk like him as well. Salman is also one of the fittest actors in Bollywood, and he doesnt shy away from showing off how ripped he is. He is also witty, and has quick come-backs during interviews or TV show appearances. Life imitates art and vice versa. This statement is true for Salman Khan, if not anyone else in Bollywood.

Is it a bad thing that the distinction between Salman the superstar and his characters, is blurry? Not necessarily. Salman has been profiting off of this image since 2009. He is arguably one of the most successful stars of Bollywood, if not the most. What does an actor want more than a guarantee that their films would always be successful?

On the other end of the spectrum, watching Salman in similar films makes it difficult for audiences to digest him in different kinds of roles. Hence, he is likely not offered different kinds of roles. However, at the end of the day, it is Salmans choice if he wants to prioritise his films success over a diverse filmography. As the old adage goes to each their own.

Read all the Latest News, Breaking News and Coronavirus News here

Read the original post:

Is Radhe-Your Most Wanted Bhai an Extension of Salman Khans Real Life Personality? - News18